C12N 2710/16411
Rhadinovirus
Official title: Rhadinovirus, e.g. human herpesvirus 8
C12N2710/16411 (Rhadinovirus) appears on 74 US grants and 56 published applications in this corpus.
Search patents in C12N- Granted patents
- 74
- Published applications
- 56
- Assignees
- 57
- Inventors
- 145
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 10 | 0 |
| 1999 | 7 | 0 |
| 2000 | 11 | 0 |
| 2001 | 7 | 0 |
| 2002 | 3 | 3 |
| 2003 | 6 | 2 |
| 2004 | 2 | 4 |
| 2005 | 2 | 3 |
| 2006 | 2 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 0 | 1 |
| 2011 | 3 | 7 |
| 2012 | 2 | 4 |
| 2013 | 2 | 3 |
| 2014 | 0 | 2 |
| 2015 | 4 | 2 |
| 2016 | 2 | 1 |
| 2017 | 0 | 2 |
| 2018 | 4 | 2 |
| 2019 | 0 | 2 |
| 2020 | 2 | 1 |
| 2021 | 1 | 1 |
| 2022 | 0 | 2 |
| 2023 | 0 | 1 |
| 2024 | 1 | 2 |
| 2025 | 0 | 6 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16422New viral proteins or individual genes, new structural or functional aspects ofIndexing code56
- C12N 2710/16434Use of virus or viral component as vaccineIndexing code15
- C12N 2710/16441Use of virus, viral particle or viral elements as a vectorIndexing code12
- C12N 2710/16451Methods of production or purification of viral materialIndexing code5
- C12N 2710/16471Demonstrated in vivo effectIndexing code2
- C12N 2710/16421Viruses as suchIndexing code1
- C12N 2710/16423Virus like particles [vlp]Indexing code1
- C12N 2710/16433Use of viral protein as therapeutic agent other than vaccineIndexing code1
Recent patents
- Transcription active complex targeting cancer drug from viral protein sequence20 Jan 2026US 12,528,840 B2The Regents of the University of California
- Multivalent Kaposi sarcoma-associated herpesvirus-like particles and uses thereof3 Dec 2024US 12,156,911 B2City of Hope
- Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors19 Oct 2021US 11,149,255 B2BioVentures, LLC
- Turkey herpesvirus vectored recombinant containing avian influenza genes19 May 2020US 10,655,146 B2Biomune Company
- Inhibition of TCR signaling with peptide variants21 Jan 2020US 10,538,558 B2Signablok, Inc.
- Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors16 Jul 2026US 2026/0199414 A1Turnstone Biologics Corp.
- Engineered gene effectors, compositions, and methods of use thereof25 Dec 2025US 2025/0388634 A1Epicrispr Biotechnologies, Inc.
- Peptide inhibitors for chromodomain helicase dna binding protein 4 (chd4)11 Sep 2025US 2025/0282834 A1The Regents of the University of California
- vIRF3-Derived Peptide and Use Thereof for Preventing or Treating Cancer21 Aug 2025US 2025/0263444 A1Korea University Research and Business Foundation, Sejong Campus
- Use of viral il-6 in cancer therapy26 Jun 2025US 2025/0206796 A1The Regents of the University of California
Most cited
By later US patents
- Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof80US 5,854,398 AThe Trustees of Columbia University in the City of New York · 1998
- Terminal complement inhibitor fusion proteins31US 5,847,082 AAlexion Pharmaceuticals, Inc. · 1998
- Unique associated Kaposi's sarcoma virus sequences and uses thereof18US 6,348,586 B1The Trustees of Columbia University in the City of New York · 2002
- Unique associated Kaposi's sarcoma virus sequences and uses thereof15US 5,801,042 AThe Trustees of Columbia University in the City of New York · 1998
- Unique associated Kaposi's sarcoma virus sequences and uses thereof15US 5,830,759 AThe Trustees of Columbia University in the City of New York · 1998